Bern M M, Hazel D, Reilly D T, Adcock D M, Hou L
Department of Medicine, New England Baptist Hospital, Boston, MA, USA.
Department of Research, New England Baptist Hospital, Boston, MA, USA.
Int J Lab Hematol. 2015 Oct;37(5):673-9. doi: 10.1111/ijlh.12384. Epub 2015 May 15.
This study examines makers of activation of clotting following three chemoprophylactic regimens used for prevention of postoperative venous thromboembolic disease (TED) following high-risk surgery for TED.
Patients having elective primary knee or hip replacement surgery received variable dose warfarin (target international normalized ratios 2.0-2.5), 1 mg warfarin daily starting 7 days preoperatively or aspirin 325 mg daily starting on the day of surgery. Twelve patients in each group were treated for 28 ± 2 days. Thrombin-antithrombin (T-AT) and prothrombin fragment F1 + 2 were measured at baseline and postoperative days 3 and 28 ± 2.
Thrombin-antithrombin and F1 + 2 on postoperative day 3 were equal for the study groups. By days 28 ± 2, variable dose warfarin therapy group suppressed production of F1 + 2 (P = 0.002) with no difference in the T-AT accumulation. F1 + 2 for other patients overlapped the normal range.
The signals of activated clotting following surgery did not differentiate the three regimens on postoperative day 3. Variable dose warfarin was associated with suppression of F1 + 2 after 1 month of therapy, with no effect on accumulation of T-AT. Fixed low-dose warfarin started 7 days prior to surgery and aspirin are not inferior on postoperative day 3, but appear to be inferior over a longer treatment.
本研究检测了用于预防高危手术后静脉血栓栓塞性疾病(TED)的三种化学预防方案后凝血激活的标志物。
接受择期初次膝关节或髋关节置换手术的患者接受不同剂量的华法林(目标国际标准化比值为2.0 - 2.5),术前7天开始每日服用1毫克华法林,或术后当天开始每日服用325毫克阿司匹林。每组12名患者接受28±2天的治疗。在基线、术后第3天和28±2天测量凝血酶 - 抗凝血酶(T - AT)和凝血酶原片段F1 + 2。
术后第3天,各研究组的凝血酶 - 抗凝血酶和F1 + 2水平相当。到28±2天时,不同剂量华法林治疗组抑制了F1 + 2的产生(P = 0.002),而T - AT的积累无差异。其他患者的F1 + 2水平在正常范围内。
术后第3天,三种方案的手术凝血激活信号无差异。治疗1个月后,不同剂量华法林与F1 + 2的抑制有关,对T - AT的积累无影响。术前7天开始使用的固定低剂量华法林和阿司匹林在术后第3天并不逊色,但在更长疗程中似乎较差。